Zacks Earnings Trends Highlights: Royal Caribbean and Danaher

In This Article:

For Immediate Release

Chicago, IL – January 30, 2025– Zacks Director of Research Sheraz Mian says, "Total earnings for the 112 S&P 500 companies that have reported results are up +10.8% from the same period last year on +5.5% higher revenues, with 80.4% beating EPS estimates and 68.8% beating revenue estimates."

Broad-Based Sector Growth Expected for 2025

Note: The following is an excerpt from this week's Earnings Trends report. You can access the full report that contains detailed historical actual and estimates for the current and following periods, please click here>>>

Here are the key points:

  • Total earnings for the 112 S&P 500 companies that have reported results are up +10.8% from the same period last year on +5.5% higher revenues, with 80.4% beating EPS estimates and 68.8% beating revenue estimates.

  • The picture emerging from the 2024 Q4 earnings season continues to be one of strength and improving outlook, with the companies not only coming ahead of estimates but also providing reassuring guidance for the coming quarters.

  • If actual 2025 earnings results turn out to be as currently expected, this will be the first time since 2018 when all 16 Zacks sectors achieved positive earnings growth (to be precise, the Zacks Autos sector had modestly negative earnings growth in 2018).

  • We continue to believe that the best things that can happen this earnings season will be for management teams to validate the robust and broad-based earnings growth expected in 2025.

Notable Earnings Results

Just to feature two recent reports, the strong results from Royal Caribbean RCL contrast with the underwhelming guidance in the Danaher Corp. DHR report.

Royal Caribbean shares have more than doubled over the past year, and the company's quarterly report and guidance suggest plenty of operating momentum to justify this stock market performance. Royal Caribbean's Q4 earnings increased +34.4% from the year-earlier level on +12.9% higher revenues. While the company's guidance represented an upside to consensus estimates, the analysts following the company noted conservatism in the numbers and wouldn't be surprised if guidance was raised again in the coming months thanks to the all-around strength in demand.

Danaher's results came a hair short of the estimates that reflected its pre-announcement, but the market's bigger disappointment likely reflected the weak guidance. Shares of this maker of medical and commercial products have been laggards lately, down -2.5% this month vs. +3.2% gain for the S&P 500 index.